Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-059756
Filing Date
2026-05-13
Accepted
2026-05-13 07:06:20
Documents
48
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q plx-20260331x10q.htm   iXBRL 10-Q 906547
2 EX-10.1 plx-20260331xex10d1.htm EX-10.1 76183
3 EX-31.1 plx-20260331xex31d1.htm EX-31.1 12507
4 EX-31.2 plx-20260331xex31d2.htm EX-31.2 12690
5 EX-32.1 plx-20260331xex32d1.htm EX-32.1 6748
6 EX-32.2 plx-20260331xex32d2.htm EX-32.2 6776
  Complete submission text file 0001104659-26-059756.txt   3679905

Data Files

Seq Description Document Type Size
7 EX-101.SCH plx-20260331.xsd EX-101.SCH 24400
8 EX-101.CAL plx-20260331_cal.xml EX-101.CAL 43713
9 EX-101.DEF plx-20260331_def.xml EX-101.DEF 82546
10 EX-101.LAB plx-20260331_lab.xml EX-101.LAB 179391
11 EX-101.PRE plx-20260331_pre.xml EX-101.PRE 147390
52 EXTRACTED XBRL INSTANCE DOCUMENT plx-20260331x10q_htm.xml XML 447595
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 26970891
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)